The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants

• DOI: 10.1007/s00401-016-1643-0
• Publication Date: 2016-11-17T06:21:04Z
• Authors: Kristian W. Pajtler; Stephen C. Mack; Vijay Ramaswamy; Christian A. Smith; Hendrik Witt; Amy Smith; Jordan R. Hansford; Katja von Hoff; Karen D. Wright; Eugene Hwang; Didier Frappaz; Yonehiro Kanemura; Maura Massimino; Cécile Faure-Conter; Piergiorgio Modena; Uri Tabori; Katherine E. Warren; Eric C. Holland; Koichi Ichimura; Felice Giangaspero; David Castel; Andreas von Deimling; Marcel Kool; Peter B. Dirks; Richard G. Grundy; Nicholas K. Foreman; Amar Gajjar; Andrey Korshunov; Jonathan Finlay; Richard J. Gilber...; David W. Ellison; Kenneth D. Aldape; Thomas E. Merchant; Eric Bouffet; Stefan M. Pfister; Michael D. Taylor
• Keywords: Ependymoma; Grading (engineering); Posterior fossa

Multiple independent genomic profiling efforts have recently identified clinically and molecularly distinct subgroups of ependymoma arising from all three anatomic compartments the central nervous system (supratentorial brain, posterior fossa, spinal cord). These advances motivated a consensus meeting to discuss: (1) utility current histologic grading criteria, (2) integration molecular-based stratification schemes in future clinical trials for patients with (3) therapy context molecular subgroups. Discussion at generated series statements recommendations attendees, which comment on prognostic evaluation treatment decisions intracranial (WHO Grade II/III) based knowledge its The major among attendees was reached that (outside trials) should not be (II vs III). Supratentorial fossa ependymomas are diseases, although impact is still evolving. Molecular subgrouping part henceforth.